Stay updated on Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial

Sign up to get notified when there's something new on the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The page now presents the clinical-trial record for radiation and chemotherapy with ipilimumab followed by nivolumab for unresectable stage III NSCLC, including its terminated status, eligibility criteria, study locations, treatment plan, outcomes, and posted results.
    Difference
    52%
    Check dated 2026-11-09T13:29:35.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0, while the study page remains inaccessible with a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T13:29:55.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A site-wide banner announces an NIH transition notice about using “Super Intelligence” in place of “Artificial Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-26T15:25:49.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-19T15:09:51.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-12T15:15:40.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study record content, indicating the record is currently inaccessible. The visible layout shows the standard site chrome and an error message, replacing the prior study details and related information.
    Difference
    19%
    Check dated 2026-09-21T20:52:02.000Z thumbnail image

Stay in the know with updates to Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page.